Immunohistochemical Detections of EGFR Mutations in NSCLC
10.3779/j.issn.1009-3419.2014.09.11
- VernacularTitle:免疫组化法检测非小细胞肺癌EGFR突变的进展
- Author:
LIU CHANG
1
;
XU DONGBO
;
ZHONG DIANSHENG
Author Information
1. 天津医科大学总医院肿瘤内科
- Keywords:
Lung neoplasms;
Epidermal growth factor receptor;
Mutation;
Immunohistochemistry
- From:
Chinese Journal of Lung Cancer
2014;(9):701-705
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, it has been well known that non-small cell lung cancer (NSCLC) patients with muta-tions of epidermal growth factor receptor (EGFR) response better to EGFR-tyrosine kinase inhibitor treatment. Although DNA-based assays (e.g. DNA sequencing) are the most frequently used and a relatively reliable method to detect EGFR muta-tions, they are complex, time-consuming and relatively expensive for routine use in clinical laboratories, besides they require high quality tumor samples. In contrast, the immunohistochemistry (IHC) methods make up fully for the above shortcomings and can serve as screening tests for EGFR mutations. However, there are many factors that can inlfuence the results of IHC methods, such as different staining procedures, different antigen retrieval solutions and different sets of criteria, etc. hTus the IHC methods for detecting EGFR mutations have not been widely used in clinic and only in the research stage. hTis article re-views the use of IHC methods by different researchers and further discusses how to make the IHC methods work best for the detection of EGFR mutations.
